CDER Reorganization Creates Drug Safety “Super-Office”; Management Support Is Goal
Executive Summary
Elevation of the Center for Drug Evaluation and Research’s Office of Surveillance and Epidemiology to a “super-office” is expected to provide greater management support to the drug safety unit’s growing number of staff and responsibilities.
You may also be interested in...
People In The News: Tracking The Latest Industry Personnel Moves
deBethizy steps down as president and CEO at Targacept; new CEOs at Trophos and Cytheris; Dal Pan named permanent director of FDA Office of Surveillance and Epidemiology; more personnel announcements in this month’s column.
FDA's Office of Medical Policy Grows Into A "Super Office"; DDMAC Gets A Promotion
The Office of Medical Policy now houses the Office of Prescription Drug Promotion (formerly DDMAC) and the newly created Office of Medical Policy Initiatives.